{
  "nctId": "NCT03348592",
  "briefTitle": "Gut Microbiome and p-Inulin in CKD - TarGut CKD Study",
  "officialTitle": "Gut Microbiome and p-Inulin in CKD TarGut CKD Study",
  "protocolDocument": {
    "nctId": "NCT03348592",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2016-09-28",
    "uploadDate": "2017-10-18T13:51",
    "size": 733619,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03348592/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 18,
    "enrollmentType": "ESTIMATED"
  },
  "timeline": {
    "startDate": "2016-10",
    "completionDate": "2018-06",
    "primaryCompletionDate": "2017-11",
    "firstSubmitDate": "2017-10-31",
    "firstPostDate": "2017-11-21"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n1. Subjects with eGFR 15.0 to 50.0 ml/min/1.73 m2 as estimated by the CKD-EPI equation\n2. Albuminuria greater than 300 mg/g creatinine (by spot urine test) if eGFR is ≥45 ml/min/1.73 m2\n3. Age ≥ 18 years\n4. For women of childbearing potential, willingness to use a highly effective method of birth control for up to 4 weeks after the last dose to study drug. See Section 4.2.1 for definition of childbearing potential and acceptable methods of birth control\n5. Ability to provide informed consent\n\nExclusion Criteria:\n\n1. Use of pre- or pro-biotics during the past 2 months\n2. Consumption of probiotic yogurt during the past 2 weeks\n3. Use of antibiotics within the past 3 months if the patient received a single course of antibiotic. If the patient received more than one course of antibiotic treatment, we will wait for 6 months prior to inclusion.\n4. Presence of HIV infection, chronic wound infection and osteomyelitis\n5. Presence of or treatment for periodontal infection\n6. Inflammatory bowel disease, chronic diarrhea, current C. difficile infection\n7. Cirrhosis or chronic active hepatitis\n8. Treatment with immunosuppressive medications in the past 6 months or more than a week of treatment with prednisone \\>10 mg in the last 3 months\n9. Treatment with proton pump inhibitors within the last one month\n10. Anticipated initiation of dialysis or kidney transplant within 9 months\n11. Acute on chronic kidney disease\n12. Expected survival \\< 9 months Do not disclose or use except as authorized by the Pilot Clinical Trials in CKD Consortium.\n13. Pregnancy, anticipated pregnancy, or breastfeeding\n14. Incarceration\n15. Participation in another intervention study\n16. Severe anemia defined as hemoglobin \\<9.0 g/dl any time during the last 3 months\n17. Patients in whom frequent blood sampling may be difficult",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Microbial composition of stool",
        "description": "Microbial taxonomy will be assigned using Ribosomal Database Project (RDP) for 16S, augmented by analysis of specific sequences using BLAST. The 16S tag sequences will be collected into operational taxonomic units (OTUs) with 97% sequence identity.",
        "timeFrame": "Stool is collected weekly for 28 weeks"
      },
      {
        "measure": "Adherence to p inulin prescription",
        "description": "Proportion of packets taken vs packets prescribed by packet count",
        "timeFrame": "Packets are counted every four weeks during the 12 weeks when the patient is taking p inulin"
      }
    ],
    "secondary": [
      {
        "measure": "butyrate",
        "description": "captured by untargeted metabolomics, short chain fatty acid in stool blood and urine",
        "timeFrame": "Collected weekly for 28 weeks"
      },
      {
        "measure": "propionate",
        "description": "captured by untargeted metabolomics, short chain fatty acid in stool blood and urine",
        "timeFrame": "Collected weekly for 28 weeks"
      },
      {
        "measure": "acetate",
        "description": "captured by untargeted metabolomics, short chain fatty acid measured in stool blood and urine",
        "timeFrame": "Collected weekly for 28 weeks"
      },
      {
        "measure": "Trimethylamine N oxide",
        "description": "captured by untargeted metabolomics in stool blood and urine",
        "timeFrame": "Collected weekly for 28 weeks"
      },
      {
        "measure": "Choline",
        "description": "captured by untargeted metabolomics in stool blood and urine",
        "timeFrame": "Collected weekly for 28 weeks"
      },
      {
        "measure": "Betaine",
        "description": "captured by untargeted metabolomics in stool blood and urine",
        "timeFrame": "Collected weekly for 28 weeks"
      },
      {
        "measure": "Indoles",
        "description": "Indoxyl sulfate Indoxyl glucuronide 5-hydroxyindole Indole-3-prioonic acid Indole-3-acetic acid captured by untargeted metabolomics in stool blood and urine",
        "timeFrame": "collected weekly for 28 weeks"
      },
      {
        "measure": "Phenols",
        "description": "p-cresol sulfate p-Cresol glucuronide Phenyl sulfate Phenyl glucuronide α-N-phenylacetyl-L-glutamine Phenylpropionylglycine Hippuric acid 4-hydroxybenzoate Phenylacetylglycine\n\n\\* captured by untargeted metabolomics and quantitated by targeted metabolomics in stool blood urine",
        "timeFrame": "collected weekly for 28 weeks"
      },
      {
        "measure": "polyamines",
        "description": "captured by untargeted metabolomics in stool blood and urine",
        "timeFrame": "collected weekly for 28 weeks"
      },
      {
        "measure": "metabolites of urea and creatinine metabolism",
        "description": "captured by untargeted metabolomics in stool blood and urine",
        "timeFrame": "collected weekly for 28 weeks"
      },
      {
        "measure": "Allantoin",
        "description": "captured by untargeted metabolomics in stool blood and urine",
        "timeFrame": "collected weekly for 28 weeks"
      },
      {
        "measure": "Fructose",
        "description": "captured by untargeted metabolomics in stool blood and urine",
        "timeFrame": "collected weekly for 28 weeks"
      },
      {
        "measure": "Cytokines",
        "description": "IL-1β IL-2 IL-4 IL-6 IL-10 IL-17 IL-22 TNFα measured by standard ELISA in stool",
        "timeFrame": "collected weekly for 28 weeks"
      },
      {
        "measure": "endotoxin",
        "description": "measured by standard ELISA in stool",
        "timeFrame": "collected weekly for 28 weeks"
      },
      {
        "measure": "Myeloperoxdase (MPO)",
        "description": "measured by standard ELISA in stool",
        "timeFrame": "collected weekly for 28 weeks"
      },
      {
        "measure": "hsCRP",
        "description": "measured by standard ELISA in stool",
        "timeFrame": "collected weekly for 28 weeks"
      },
      {
        "measure": "HMGB1",
        "description": "measured by standard ELISA in stool",
        "timeFrame": "collected weekly for 28 weeks"
      },
      {
        "measure": "TNF-R1",
        "description": "measured by standard ELISA in stool",
        "timeFrame": "collected weekly for 28 weeks"
      },
      {
        "measure": "TNF-R2",
        "description": "measured by standard ELISA in stool",
        "timeFrame": "collected weekly for 28 weeks"
      },
      {
        "measure": "Lipopolysaccharide binding protein (LBP)",
        "description": "measured by standard ELISA in stool",
        "timeFrame": "collected weekly for 28 weeks"
      },
      {
        "measure": "sCD14",
        "description": "measured by standard ELISA in stool",
        "timeFrame": "collected weekly for 28 weeks"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 21,
      "otherCount": 0,
      "totalCount": 23
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:06.527Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}